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Abstract
Background: The expression of DNA fragmentation factor 45 (DFF45) and B-cell lymphoma 2 (BCL2) in glands of
the normal human endometrium is related to phases of the menstrual cycle and decreases after menopause, whereas
the expression of DNA fragmentation factor 40 (DFF40) is stable. Moreover, DF45, BCL2 and DFF40 underexpression has
been reported in numerous malignancies, including uterine leiomyosarcomas. In this study, we aimed to investigate
DFF45, BCL2 and DFF40 expression in endometrioid and non-endometrioid types of endometrial cancers (ECs).
We also evaluated the correlations between DFF45, BCL2 and DFF40 expression levels and clinicopathological
parameters and determined the value of these three proteins as prognostic markers of disease-free survival (DFS)
and overall survival (OS).
Methods: Immunohistochemistry was performed to evaluate DFF45, BCL2 and DFF40 expression in 342
cases of ECs. Student’s t-test, the Mann-Whitney U-test, and the chi-squared test were used for the
statistical analyses as appropriate. The Cox-Mantel test, Cox’s proportional hazard model, and relative risk
analyses were used to evaluate associations between DFF40, DFF45, and BCL2 expression and clinicopathological
characteristics.
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Results: DFF40 and BCL2, but not DFF45, were significantly underexpressed in non-endometrioid and high-grade
endometrioid ECs compared with low- and moderate-grade endometrioid ECs. Women with DFF40- and BCL2-
negative tumors had higher risks of disease recurrence, lymph node involvement, lympho-vascular space infiltration,
and deep myometrial invasion compared with women with DFF40- and BCL2-positive tumors. Additionally, women
with DFF40- and BCL2-negative tumors had significantly lower OS and DFS than women with DFF40- and BCL2-
positive tumors. A multivariable analysis of the model, including the clinicopathological characteristics and
immunohistochemical results, showed that negative BCL2 expression, lymph node involvement, and high-stage
and high-grade disease were independent predictors of OS, whereas negative BCL2 expression, lymph node
involvement, and high-stage disease were independent predictors of DFS.
Conclusions: Compared with low- and moderate-grade endometrioid ECs, non-endometrioid and high-grade
endometrioid ECs showed significant DFF40 and BCL2 underexpression. The absence of DFF40 and BCL2 expression
negatively affects DFS and OS. Further prospective studies are warranted to assess the potential utility of DFF40 and
BCL2 as targets in the diagnosis or treatment of ECs.
Keywords: B-cell lymphoma 2 (BCL2), DNA fragmentation factor 40 (DFF40), DNA fragmentation factor 45 (DFF45),
Endometrial cancers (ECs), Disease-free survival (DFS), Overall survival (OS)
Background
Endometrial cancers (ECs) have the highest incidence
among female genital tract malignancies in economically
prosperous populations [1, 2]. Epithelial malignant tu-
mors of the uterus include pure endometroid cancers
grade 1-3, uterine serous carcinomas, clear cell carcin-
omas, and carcinosarcomas [3]. According to their clin-
ical features, Bokhman divided ECs into two groups:
estrogen-dependent type 1 malignancies, which typically
occur during the perimenopausal period and have a fa-
vorable prognosis, and estrogen-independent type 2 ma-
lignancies, the incidence of which is highest among
individuals 70 years of age with a poor prognosis [4].
Subsequent studies have confirmed that type 1 and type
2 ECs differ with respect to their morphologies and mo-
lecular characteristics. Pure endometrioid ECs are histo-
logically heterogeneous and present different patterns of
myometrial invasion [5]. To describe an unusual type of
this invasion, Murra et al. introduced the acronym
“MELF” for microcystic, elongated and fragmentated
pattern of myometrial invasion in endometrioid ECs, but
they failed to demonstrate a statistically significant effect
of MELF on overall survival – only a subgroup of
women showing a fibromyxoid stromal reaction and
MELF had improved survival [6]. Further studies have
revealed that the incidence of MELF in ECs is between
13% and 36% and have shown that its presence is signifi-
cantly associated with tumor size, lymph node involve-
ment, advanced International Federation of Gynecology
and Obstetrics (FIGO) stage, lympho-vascular space in-
volvement (LVSI+), mucinosus differentiation, and papillary
architecture [7–10]. In contrast to the findings reported by
Murray et al. and Kihara et al., who did not demonstrate
any association between MELF and disease-free or overall
survivals, Zinkov et al. observed a significantly lower
survival rate in patients with endometrioid ECs with a
MELF pattern compared with MELF-negative women
[6, 7, 11].
Type 2 malignancies are characterized by p53 and
PIK3CA overexpression, and type 1 malignancies are
characterized by PTEN mutations [12]. High-grade early-
stage ECs display SOX-2 overexpression and low gamma-
glutamyltransferase expression but not Oct4 overexpres-
sion. SOX-2 and Oct4 are cancer stem cell markers that
have been hypothesized to be responsible for carcinoma
infiltration, and gamma-glutamyltransferase acts as an
antioxidant and thus protects cells against oxidative stress
[13, 14]. Type 2 ECs also display increased proliferation
and apoptosis rates [15].
Burstman was the first to investigate the role of DNA
fragmentation factor 45 (DFF45) in ECs [16]. The DNA
fragmentation factor (DFF) complex is localized to the cell
nucleus and exists as a dimer comprising DFF40 (caspase-
activated DNase; CAD) and DFF45 (inhibitor of caspase-
activated DNase; ICAD) [17]. DFF45 is cleaved by
caspase-9 at the end of the apoptotic cascade, which re-
sults in the release of DFF40 from the DFF40/DFF45 com-
plex, leading to DFF40-mediated DNA fragmentation
(DNA laddering) [10]. However, DFF45 is not merely an
inhibitor of DFF40, as its presence is also required for the
proper folding of DFF40, which is necessary for produc-
tion of the active protein [17, 18]. In our recent studies,
we have demonstrated DFF40 and DFF45 overexpression
in endometrial polyps and benign endometrial hyperplasia
compared with control endometrium [19]. Moreover, we
have shown that uterine leiomyosarcomas are character-
ized by DFF40 and DFF45 underexpression compared
with case and control myometrium; women whose tumors
were negative for DFF40 presented significantly shorter
disease-free survival and overall survival [20].
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BCL2 is a well-known inhibitor of apoptosis that is re-
sponsible for stabilizing mitochondrial membranes and
thus preventing cells from undergoing apoptosis via the
mitochondrial pathway [21, 22]. BCL2 underexpression
has been linked to more aggressive ECs, including high-
grade cancers, advanced stage cancers, and cancers dis-
playing lymph node invasion [23]. In contrast to benign
endometrial polyps, significant BCL2 underexpression
has been shown in the stromal layer of benign hyper-
plastic endometrium [18].
The aim of this work was to evaluate the relationship
between the immunohistochemical expression patterns of
DFF45 and DFF40 and those of BCL2 and to assess the
correlations between the expression of these biomarkers
and the clinicopathological characteristics of ECs.
Methods
Patient and tumor characteristics
This study was performed using archived paraffin-
embedded tissue samples from patients who were diag-
nosed with and treated for ECs in the Gynecology and On-
cology Clinic of Jagiellonian University, Krakow, Poland.
Samples from 365 patients who were consecutively diag-
nosed with EC from January 2007 to December 2012 were
initially considered eligible for inclusion in the study; how-
ever, the medical records for 24 of these women were
found to have missing data, and the samples from an add-
itional 17 patients underwent autolysis. Thus, samples
from 342 patients were ultimately eligible for inclusion in
the study. Each patient was preoperatively diagnosed with
EC based on the results of endometrial evaluations per-
formed via dilatation and curettage (D&C) or hysteroscopy
with biopsy. Each patient also underwent pelvic ultrasound
or pelvic magnetic resonance imaging, abdominal ultra-
sound, and chest X-ray or chest computed tomography
preoperatively. Each patient subsequently underwent total
hysterectomy with bilateral salpingo-oophorectomy with
or without pelvic lymph node biopsy, and patients with an
increased risk of disease recurrence and/or nodal metasta-
ses underwent radical surgery and/or pelvic/para-aortal
lymph node dissection. The omentum was removed in pa-
tients with tumors with histology corresponding to serous
carcinoma, clear cell carcinoma, or carcinosarcoma. Each
postoperative specimen was re-evaluated by two experi-
enced pathologists, who were blinded to each other’s inter-
pretations and to previous pathology reports, to confirm
the final diagnosis of EC. All cases were restaged using
current FIGO 2010 criteria [3]. Moreover, histological typ-
ing, grading (G), and the presence of MELF pattern myo-
metrial invasion in the patients’ paraffin-embedded tissue
specimens were performed according to the classification
of the World Health Organization (WHO) and criteria pre-
sented by Murray et al. [6, 24] Body mass index (BMI) was
calculated by dividing body mass, as determined by
preoperative measurements of standardized morning
weights, by the square of the body height (kg/m2), as
determined by preoperative measurements of height. The
date of menopause onset was defined as the date of the
final menstrual period, i.e., the date after which no menses
were reported for a subsequent period of 12 months. Sub-
cohorts comprising patients with G1-2 endometrial adeno-
carcinoma (Group 1) and patients with non-endometrioid
EC and G3 endometrial adenocarcinoma (Group 2) were
subsequently organized. The characteristics of these pa-
tients and their tumors are presented in Table 1.
Sample preparation
Representative postoperative tissue blocks were identified
for immunohistochemical analysis. Four specimens from
four patients with stage 4 disease that were obtained by
D&C were also included in the analysis. Immunohisto-
chemical staining was performed with a rabbit polyclonal
antibody against DFF40 (Abcam, Cambridge, UK) diluted
1:50, a monoclonal mouse anti-human antibody against
BCL2 (Leica Biosystems Newcastle Ltd., Newcastle Upon
Tyne, UK) diluted 1:200 and a rabbit polyclonal antibody
against DFF45 (Abcam, Cambridge, UK) diluted 1:100
using a previously described protocol [19, 20].
Sections that were stained but incubated without a pri-
mary antibody were used as negative controls. Jurkat cells
(for DFF45 and DFF40) and human follicular lymphoma
cells (for BCL2) were used as positive controls.
Immunohistochemical scoring
To obtain comparable outcomes to our formerly published
results, the following procedure, which was previously devel-
oped and validated, was employed: two certified histopathol-
ogists, who were blinded to the study data and to each
other, calculated the staining scores for DFF40, BCL2 and
DFF45 for each slide in five high-power fields (× 40) using a
0-to-3 scale (0, no staining; 1, weak staining; 2, moderate
staining; and 3, strong staining) [19, 20]. The cell staining
percentage scores for DFF45 and DFF40 were determined
as follows: 0 = expression in up to 10% of cells; 1+ = expres-
sion in 10–50% of cells; 2+ = expression in 51–80% of cells;
and 3+ = expression in over 80% of cells. The cell staining
percentage scores for BCL2 were calculated using the scale
defined by Yigit et al.: 0 = expression in up to 5% of cells; 1+
= expression in 5%-25% of cells; 2+ = expression in 26%-50%
of cells; and 3+ expression in over 50% of cells [25]. The in-
tensity score was multiplied by the cell staining percentage
score to obtain the final immunoreactivity score for each
protein, which ranged from 0 to 9. Final scores of 0-1 were
indicative of negative protein expression, whereas scores of
2-4 were indicative of low protein expression, and scores of
6-9 were indicative of high protein expression. Discrepancies
regarding scoring were noted in 1.75% of the cases. In these
instances, the corresponding samples were re-evaluated
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2 weeks after the primary evaluation to achieve consensus
regarding their scores and to minimize the possibility that
the results of analysis would be affected by recall bias.
Statistical analysis
The clinical characteristics of the study groups were com-
pared using the parametric Student’s t-test and the non-
parametric Mann–Whitney U test as appropriate. The data
are presented as the mean ± standard deviation (SD) or as
the median ± standard error of the mean (SEM). The chi-
squared test was employed to evaluate differences in bio-
marker immunoexpression, with Yate’s correction, if re-
quired, based on the expected frequencies of variables.
Cox’s proportional hazard model was used to determine
the hazard ratios (HRs) and corresponding 95% confidence
intervals (CIs) for the survival predictors. The Cox–Mantel
test was used to compare OS (defined as the period be-
tween the initial surgery and time of death) and DFS
(defined as the period between the initial surgery and time
of disease recurrence), and the relative risks (RRs) of the
factors associated with a poor prognosis were calculated for
cases in which DFF40, DFF45, or BCL2 expression was
negative. To evaluate interobserver/intraobserver agree-
ment for the immunohistochemistry scores, we calculated
the intraclass correlation coefficient (ICC) and correspond-
ing 95% CIs for multiple histopathological evaluations. For
these evaluations, Research Randomizer (www.randomizer.
org) was employed to select 50 samples in which DFF40,
DFF45, and BCL2 expression levels were re-evaluated at
2 weeks after the primary evaluation to prevent recall bias
from affecting the study results. The Guidelines for Report-
ing Reliability and Agreement in Studies were used to verify
these results [26]. Calculations were performed using STA-
TISTICA data analysis software, version 12.0 (StatSoft, Inc.
2014. STATISTICA data analysis software system, version
12. www.statsoft.pl), and MedCalc Statistical Software,
Table 1 Baseline clinicopathological characteristics of studied endometrial cancers cohorts
Entire Cohort
N = 342
Group A
N = 215
Group B
N = 127
p*
Histology Endometrioid and non-endometrioid
endometrial cancers
Low- and moderate- grade
endometroid endometrial cancer
Non-endometrioid and high-grade
endometroid endometrial cancer
Age [years] (mean ± SD**) 67.424 ± 8.399 65.167 ± 6.661 71.244 ± 9.599 < 0.0001#
BMI [kg/m2] (mean ± SD**) 24.945 ± 3.195 25.774 ± 3.488 23.542 ± 1.952 < 0.0001#
Stage*** < 0.0001#
1 174 (50.88%) 133 (61.86%) 41 (32.28%)
2 93 (27.19%) 45 (20.93%) 48 (37.80%)
3 71 (20.76%) 35 (16.28%) 36 (28.35%)
4 4 (1.17%) 2 (0.93%) 2 (1.57%)
Grade < 0.0001#
1 90 (26.31%) 90 (41.86%) 0 (0.00%)
2 132 (38.60%) 125 (58.14%) 7 (5.51%)
3 120 (35.09%) 0 (0.00%) 120 (94.49%)
MI***≥ 50% 258 (75.44%) 148 (68.84%) 110 (86.61%) 0.0002#
+LN& 40 (11.70%) 15 (7.44%) 25 (19.68%) 0.0004#
+LVSI&& 94 (27.49%) 42 (19.53%) 52 (40.94%) < 0.0001#
+MELF&&& 18 (5.26%) 18 (8.37%) 0 (0.00%) < 0.0001#
Adjuvant therapy < 0.0001#
VBTHA 175 (51.17%) 107 (49.77%) 68 (53.54%)
ERTHB 26 (7.61%) 0 (0.00%) 26 (20.47%)
CHTC 33 9.65%) 32 (14.88%) 1 (0.79%)
HTHD 2 (0.58%) 2 (0.92%) 0 (0.00%)
VBTHA + ERTHB 10 (2.92% 0 (0.00%) 10 (7.87%)
ERTHB + CHTC 25 (7.31%) 3 (1.39%) 22 (17,33%)
none 71 (20.76%) 71 (33.04%) 0 (0.00%)
Recurrence 46 (13.45%) 20 (9.30%) 26 (20.47%) 0.0034#
* Comparison between Groups A and B; *SD – standard deviation; *** stage of disease according to the 2010 (FIGO) classification; ***MI - myometrial invasion;
&LN - lymph node involvement; &&LVSI - lymphovascular space invasion; #statistically significant p-value; AVBTH – vaginal brachytherapy; BERTH – external
radiotherapy; CCHT – chemotherapy; DHTH – hormonal therapy
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version 16.2.1 (MedCalc Software by Ostend, Belgium). A p
value of 0.05 was considered statistically significant.
Results
Clinical characteristics
A total of 342 patients were included in analysis. The
median follow-up duration was 64 (IQR: 42.00; range:
11-106) months. Multivariate analysis showed that stage
3+ disease (HR: 4.811; CI: 2391-9.681; p < 0.001), G3 dis-
ease (HR: 3.040; CI: 1.474-6.2711; p = 0.003), lymph node
metastases (LN+) (HR: 2.834; CI:1.447-3.730; p = 0.002),
and LVSI+ (HR: 1.976; CI: 1.047-3.730; p = 0.036) were
significant predictors of OS, while age, BMI, positive
peritoneal washings, and adjuvant therapy were not in-
dependent predictors of OS. Multivariate analysis also
showed that stage 3+ disease (HR: 3.354; CI: 1.643-6.
846; p < 0.001), LN+ (HR: 3.561; CI: 1.831-6.924; p = 0.
001), and LVSI+ (HR: 2.068; CI: 1.108-3.862; p = 0.023),
but not G3, age, BMI, positive peritoneal washings, or
adjuvant therapy, were independent predictors of DFS.
The clinicopathological characteristics of the study co-
hort and its sub-groups are shown in Table 1.
DFF40, DFF45, and BCL2 immunohistochemical expression
DFF40 and DFF45 displayed predominately nuclear ex-
pression, while BCL2 displayed cytoplasmic expression
in all histological types of EC analyzed herein (Fig. 1).
No differences in DFF40, DFF45, or BCL2 expression
were observed between G1 ECs and G2 ECs in Group
A, and no differences in DFF40, DFF45, and BCL2 ex-
pression were observed between G3 ECs and non-
endometrioid tumors in Group B (Table 2). However,
DFF40 and BCL2 expression levels were significantly
higher in Group A than in Group B (p < 0.001 and p < 0.
001; respectively). DFF45 expression levels did not differ
between Groups A and B (Table 2).
The absence of DFF40 expression significantly in-
creased the RRs for disease recurrence, LN+, LVSI+,
and invasion of more than 50% of the myometrium (MI
> 50%) in the entire cohort and in Group B (with the
exception of the RR for MI > 50% in Group B) (Table 3).
Similarly, BCL2 deficiency increased the RRs for disease
recurrence, LN+, LVSI+, and MI > 50% in the entire co-
hort and in Groups A (with the exception of the RR for
disease recurrence in Group A) and B (with the excep-
tion of the RR for MI > 50% in Group B). The absence
of DFF45 expression was not associated with increases
in the risks of any of the above factors, either in the en-
tire cohort or in Group A or B (Table 3).
DFF40-negative cases showed significantly shorter OS
in the entire cohort and in Group A and displayed signifi-
cantly shorter DFS in the entire cohort, but not in Group
A or B, compared with DFF40-positive cases (Fig. 2).
DFF45 expression did not affect OS or DFS in the entire
cohort or in Group A; however, DFF45-negative patients
in Group B exhibited shorter DFS, but not OS. BCL2-
negative patients displayed significantly shorter OS in the
entire cohort and in Groups A and B compared with
BCL2-positive patients (Fig. 2). Similarly, BCL2-negative
patients displayed significantly shorter DFS in the entire
cohort and in Groups A and B compared with BCL2-
positive patients (Fig. 2).
Univariate analysis revealed that decreased DFF40 and
BCL2 expression (but not decreased DFF45 expression) in-
creased the negative HRs for OS (HR: 2.757; CI: 1.644-4.
624; p < 0.001 and HR: 6.277; CI: 3.522-11.189; p < 0.001;
respectively) and DFS (HR: and DFS (HR: 2.937; CI: 1.680-
5.134; p < 0.001 and HR: 6.979; CI: 3.654-13.331; p < 0.001;
respectively) in the entire cohort. We subsequently per-
formed multivariate analysis of the relationships among
the clinical features and DFF40, DFF45, and BCL2 expres-
sion levels and OS and DFS in the entire cohort. The re-
sults showed that stage 3+ disease (HR: 3.605; CI: 1.763-7.
372; p < 0.001), G3 disease (HR: 2.467; CI: 1.845-5.135; p =
0.016), LN+ (HR: 3.290; CI: 1.865-5.805; p < 0.001), and
BCL2 negativity (HR: 3.105; CI: 1.654-5.827; p < 0.001), but
not LVSI+, MI > 50%, age, positive peritoneal washings, ad-
juvant therapy, or DFF40 or DFF45 negativity, were signifi-
cant predictors of OS. Additionally, stage 3+ (HR: 2.682;
CI: 1.312-5.487; p = 0.007), LN+ (HR: 3.997; CI: 2.217-
7205; p < 0.001), and BCL2 deficiency (HR: 2.302; CI: 2.
302-8.777; p < 0.001) were significant predictors of DFS.
Validation of the reliability of the immunohistochemistry
scores
We noted very high intra-rater agreement with regard to
the immunohistochemistry scores for DFF40, DFF45,
and BCL2 expression. The ICCs for agreement between
the immunohistochemistry scores for the indicated pro-
teins, which were determined by the abovementioned
pathologists, are listed below.
A) The ICCs for agreement between the scores for
DFF40, DFF45, and BCL2 expression determined by
the first pathologist (that is, observer 1 vs. observer
1 after 2 weeks) were 0.903 (CI: 0.875–0.968), 0.887
(CI: 0.823–0.986), and 0.919 (CI: 0.893–0.983),
respectively.
B) The ICCs for agreement between the scores for
DFF40, DFF45, and BCL2 expression determined by
the second pathologist (that is, observer 2 vs.
observer 2 after 2 weeks) were 0.934 (CI: 0.889–
0.961), 0.898 (CI: 0.831–0.929), and 0.984 (CI:
0.972–0.990), respectively.
As full inter-rater consensus was achieved for the ex-
pression levels of the above proteins, we did not evaluate
inter-observer reliability.
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Discussion
The study evaluates DFF45, BCL2 and DFF45 expression
in ECs and assesses the relationships between DFF40
and clinical and histopathological factors. Although
Buchman’s clinical classification of ECs into two groups
has been validated in numerous molecular studies, it is
currently being revised based on advances in cancer epi-
demiological research. Based on the results of a case-
control study nested in the Women’s Health Imitative
Observational Study, Suarez et al. and Brinton et al. have
Fig. 1 DFF40*, DFF45**, and BCL2*** expression (× 200) in different histological types of endometrial cancers. *DNA fragmentation factor 40;
**DNA fragmentation factor 45; ***B-cell lymphoma 2 protein; $Endometrial cancer
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Table 2 Immunoexpression of DFF40*, DFF45**, and BCL2*** in endometrial cancers in relation to histological type and study groups
A and B
Low and moderate-grade endometroid cancer
(Group A)
pA Non-endometrioid and high-grade endometroid endometrial cancer
(Group B)
pB
Tumor histology EAC-G1$
N = 90
EAC-G2$$
N = 125
Carcinosarcomas
N = 31
Serosus tumor
N = 22
Clear cell tuor
N = 25
EAC-G3$$$
N = 49
DFF40*
High 31 (34.44%) 28 (22.40%) 0.143 5 (16.13%) 2 (9.09%) 1 (4.00%) 4 (8.16%) 0.754
Low 33 (36.67%) 52 (41.60%) 6 (19.35%) 3 (13.64%) 6 (24.00%) 11 (22.45%)
Negative 26 (28.89%) 45 (36.00%) 20 (64.52%) 17 (77.27%) 18 (72.00%) 34 (69.39%)
pAB < 0.001#
DFF45**
High 1 (1.11%) 0 (0.00%) 0.409 1 (3.22%) 0 (0.00%) 0 (0.00%) 2 (4.08%) 0.935
Low 7 (7.78%) 13 (10.40%) 3 (9.68%) 2 (9.09%) 3 (12.00%) 10 (20.41%)
Negative 82 (9.11%) 112 (89.6%) 27 (87.10%) 20 (90.91%) 22 (88.00%) 37 (75.51%)
pAB = 0.101
Bcl-2***
High 29 (32.22%) 44 (35.20%) 0.523 2 (6.45%) 1 (4.55%) 1 (4.00%) 5 (10.21%) 0.187
4 (12.90%) 4 (18.18%) 3 (12.00%)Low 34 (37.78%) 38 (30.40%) 16 (32.65%)
Negative 27 (30.00%) 43 (34.40%) 25 (80.65%) 17 (77.27%) 21 (84.00%) 28 (57.14%)
pAB < 0.001#
pA – chi-squared test in Group A; pB – chi-squared test in Group B; pAB – chi-squared test between Group A and Group B; $endometrial adenocarcinoma grade 1;
$$endometrial adenocarcinoma grade 2; $$$endometrial adenocarcinoma grade 3; *DFF40 – DNA fragmentation factor 40; **DFF45 – DNA fragmentation factor 45;
***BCL2 – B-cell lymphoma 2
Table 3 Relative risks (RRs) and 95% confidence intervals (CIs) of recurrence (R+), lymph node involvement (LN+), lymphovascular
space invasion (LVSI+), and myometrial invasion over 50% (MI > 50%) in patients with DFF40*-, DFF45**-, and BCL2***-negative
endometrial cancers
Low and moderate-grade endometroid
cancer (Group A)
Non-endometrioid and high-grade endometroid
endometrial cancer (Group B)
Total cohort
R+
DFF40* 1.611 (CI:0.694-3.741; p = 0.267) 7.423 (CI: 1.048-52.599; p = 0.046) 2.435 (CI: 1.365-4.343; p = 0.002)
DFF45** 0.892 (CI:0.222-3.581; p = 0.871) 1.843 (CI: 0.608-5.586; p = 0.280) 1.211 (CI:0.506-2.898; p = 0.668)
BCL-2*** 2.048 (CI: 0.821-5.081; p = 0.121) 12.847 (CI: 1.805-91.464; p = 0.012) 4.192 (CI: 2.128-8.261; p < 0.001)
LN+
DFF40* 1.033 (CI:0.567-1.766; p = 0.915) 7.422 (CI:1.048-52.594; p = 0.045) 4.19 (CI: 1.88-9.33; p < 0.001)
DFF45** 0.433 (CI:0.133-1.412; p = 0.166) 1.161 (CI: 0.441-3.060; p = 0.763) 0.70 (CI: 0.33-1.48; p = 0.344)
BCL-2*** 3.386 (CI:1.256-9.127; p = 0.015) 3.624 (CI:1.493-11.424; p-0.028) 4.36 (CI: 2.14-8.87; p < 0.001)
LVSI+
DFF40* 0.947 (CI: 0.508-1.767; p = 0.865) 2907 (CI: 1.273-6.641; p = 0.011) 1.953 (CI:1.360-2.803;p < 0.001)
DFF45** 0.844 (CI: 0.374-1.907; p = 0.684) 1.736 (CI: 0.846-3.563; p = 0.133) 1.378 (CI: 0.749-2.537; p = 0.303)
BCL-2*** 2.483 (CI: 1.459-4.226; p < 0.001) 3.624 (CI:1.493-11.424; p-0.028) 3.089 (CI:2.075-4.599; p < 0.001)
MI > 50%
DFF40* 1.058 (CI: 0.873-1.283; p = 0.562) 1.183 (CI:0.962-1.456; p = 0.112) 1.216 (CI: 1.078-1.270; p = 0.001)
DFF45** 1.057 (CI: 0.668-1.672; p = 0.812) 1.189 (CI: 0.895-1.580; p = 0.233) 1.086 (CI: 0.888-1.328; p = 0.422)
BCL-2*** 1.335 (CI: 1.332-1.574; p < 0.001) 1.073 (CI: 0.920-1.251; p = 0.369) 1.549 (CI: 1.346-1.782; p < 0.001)
*DFF40 - DNA fragmentation factor 40; **DFF45 - DNA fragmentation factor 45; ***BCL2 - B-cell lymphoma 2
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Fig. 2 Kaplan-Meier survival curves for overall and disease-free survival in DFF40*-, DFF45**-, and BCL2***-negative and positive cases in the entire
study cohort and in Groups A$ and B$$, respectively. *DFF40 - DNA fragmentation factor 40; **DFF45 - DNA fragmentation factor 45; ***BCL2 -
B-cell lymphoma 2; $Group A – includes low- and moderate-grade endometroid endometrial cancers; $$Group B – includes non-endometroid
and high-grade endometroid endometrial cancers; #p-value statistically significant
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postulated that serous endometrial tumors behave in a
manner similar to that of estrogen-dependent endomet-
rial malignancies under some circumstances [27, 28].
Yang et al. have shown that diabetes also increases the
risks of serous tumors and type I ECs, but not that of
clear cell endometrial tumors, and that it increases the
risk of type 1 ECs [29]. Regarding factors associated with
cancer prevention, Sherman et al. have postulated that
cigarette smoking, which is a well-known protective fac-
tor against type 1 ECs, also reduces the risk of serous
endometrial tumors [30]. However, the results of our
study confirmed Bokhman’s scheme, as they showed that
DFF40 and BCL2 expression levels were decreased in
non-endometrioid and high-grade endometrial tumors
compared with grade 1 and 2 ECs. These results are
consistent with those of Sakuragi et al., Morsi et al.,
Loffe et al., and Porichi et al., who reported decreased
BCL2 expression levels in ECs with increased mitotic
and apoptotic indices [31–34]. Lack of BCL2 expression
was subsequently shown to be an independent predictor
of poor prognosis in ECs, and high disease stage, high
grade, increased invasion depth, and disease recurrence
were shown to be independent prognostic factors for
shorter OS [32, 35]. We showed that BCL2 deficiency
increased the risk of lymph node involvement and LVSI
+ in both endometrioid and non-endometrioid tumors.
Additionally, we showed that BCL2 deficiency was asso-
ciated with increased risks of recurrence and deep myo-
metrial invasion in the entire cohort.
In contrast to the significance of BCL2 expression, the
implications of DFF40 and DFF45 expression alterations
in ECs have been poorly addressed. Burstmann was the
only author to show that DFF45 immunoreactivity was
increased in atypical endometrial hyperplasia compared
with normal endometrial tissue and non-atypical endo-
metrial hyperplasia, but he failed to demonstrate that
DFF45 expression differed between atypical endometrial
hyperplasia and ECs [16]. Moreover, he analyzed only 48
cases of endometrioid ECs and observed no association
between DFF45 expression and EC stage or grade [16].
Our results are consistent with those of Burstmann be-
cause as we did not observe an association between EC
type and DFF45 expression, and we did not observe an
effect of DFF45 expression on the clinical features of tu-
mors, OS, or DFS in the entire cohort or in Group A, In
contrast, only patients in Group B with DFF45-negative
expression showed lower DFS, but not OS. However,
DFF45 upregulation has been observed in ovarian serous
cancers and colon cancers, and high DFF45 expression
has been associated with poorer OS in previous studies
[36, 37]. In contrast, DFF45 expression has been re-
ported to be significantly reduced in esophageal squa-
mous cell cancers with higher stages and in those with
lymph node involvement and extensive lymphovascular
space invasion than in cancers with lower stages and
without lymph node involvement or extensive lympho-
vascular space invasion; moreover, patients with low
DFF45 expression levels have been demonstrated to have
significantly shorter OS than those with high DFF45 ex-
pression levels [38].
DFF40 expression in endometrial malignancies was a
novel issue addressed in our study because it has not been
previously investigated, and this novelty precludes direct
comparisons between our results and those of other stud-
ies. Therefore, a literature review regarding DFF40 expres-
sion in other malignancies was performed. In glioblastoma
cells, Judson et al. failed to observe DFF40 mutations,
whereas George et al. showed increased DFF40 levels dur-
ing Taxol-mediated apoptosis in different human glioblast-
oma lines [39, 40]. A lack of oligonucleosomal DNA
fragmentation in human renal cell carcinomas that are re-
sistant to apoptosis was associated with decreased DFF40
and DFF45 expression [41]. Mizuta et al. proved that the
presence of DFF40 is mandatory for DNA fragmentation
during apoptosis in Burkitt cell lymphoma, and Lucieano
et al. reported that DFF40 downregulation might be a
mechanism through which cancer cells avoid apoptosis in
this malignancy [42, 43]. Breast cancer cells with DFF40
overexpression are more sensitive to doxorubicin, acet-
azolamide, and sulfabenzamide [44, 45]. These results in-
dicate that DFF40 participates in the late stages of
apoptosis and that it can be downregulated in some malig-
nancies. We observed that DFF40 downregulation was as-
sociated with lower OS and DFS in the entire cohort and
in Group A. However, unlike BCL2 underexpression,
DFF40 underexpression was not identified as an inde-
pendent predictor of OS or DFS in our multivariate
analysis.
The current study has some limitations that must be
presented. We recognize that immunohistochemistry
might be susceptible to observer bias; however, this tech-
nique has been generally accepted for measuring DFF45
and BCL2 expression in previous studies, and the perfect
inter-rater agreement and almost perfect intra-rater cor-
relation noted herein make observer bias an insignificant
contributor to the final results [16, 19, 23, 32, 36, 46].
Furthermore, immunostaining does not enable re-
searchers to measure DFF40:DFF45 nuclear stoichiomet-
ric ratios in EC cells. Widlak et al. reported that a 1:1
DFF40:DFF45 ratio is essential for proper apoptosis, but
this parameter was not assessed in our study [47]. Al-
though the MELF pattern of myometrial invasion has
been reported to be associated with worse clinical find-
ings, we were unable to analyze its association with
DFF40, DFF45, and BCL2 and its impact on DFS and
OS expression due to the small number of identified
cases. Finally, the core strength of this study was its
comprehensive analysis of DFF40 and DFF45 expression
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and BCL2 expression in ECs. As previous studies have
reported discrepancies regarding the pathological classi-
fications of different types of ECs, all the specimens in-
cluded herein were independently re-evaluated by two
experienced pathologists to confirm their diagnoses and
classifications [48]. Additionally, the relatively large size
of the cohort, as well as the well-defined clinical charac-
teristics of the specimens included herein, allowed us to
analyze the relationships between DFF40, DFF45, and
BCL2 expression and the clinical characteristics, includ-
ing OS and DFS.
Conclusions
Non-endometrioid and high-grade endometrioid ECs
show decreased expression of DFF45, BCL2 and DFF40
compared with low- and moderate-grade endometrioid
ECs. Additionally, DFF40 and BCL2 expression, but not
DFF45 expression, together with disease recurrence,
lymph node involvement, lymphovascular space inva-
sion, and deep myometrial infiltration might predict DFS
and OS. An assessment of the relationships between
DFF40, BCL2 and DFF45 expression and the above fac-
tors would enable a better understanding of the signifi-
cance of DFF40, DFF45, and BCL2 expression in other
malignancies, and prospective studies regarding the util-
ity of DFF40 and BCL2 as prognostic factors in ECs are
warranted.
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